Drugs
Resources for You
Antimicrobial Resistance
FDA, in cooperation with other Public Health Service Agencies, has embarked on several major initiatives to address what is considered to be a major threat to the Public Health in the new millennium: the emergence of drug-resistant bacteria.
This page is designed to permit ready access to FDA and CDER (Center for Drug Evaluation and Research) activities, initiatives, policies, and information regarding antimicrobial resistance (also known as drug resistance or antibiotic resistance), both for health professionals and consumers. General and technical information on antimicrobial resistance is also available at the Centers for Disease Control (CDC) Antimicrobial Resistance Web Site. This CDC web site has an extensive catalog of information about antimicrobial resistance, including fact sheets about specific pathogens and published clinical guidelines.
Since 1996, FDA has actively addressed the issue of antimicrobial resistance through several major initiatives. As an agency composed of several separate centers, including the Center for Veterinary Medicine (CVM), Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER), Center for Devices and Radiological Health, and the Center for Food Safety and Nutrition. FDA has addressed antimicrobial resistance through a variety of initiatives. FDA participates on the Public Health Service Task Force on Antimicrobial Resistance (PHS Draft Public Health Action Plan to Combat Antimicrobial Resistance: Action Plan and Federal Register Notices).
CDER, the Center for Drug Evaluation and Research, is home to (among others) the Divisions of Anti-Infective and Ophthalmology Drug Products, Special Pathogen and Transplant Products, Antiviral Drug Products (all within the Office of Antimicrobial Products), the Division of Over-the-Counter Drug Products (within the Office of Drug Evaluation V), and the Office of Generic Drugs. These offices all have involvement in FDA's efforts to address antimicrobial resistance. (CDER organizational map)
Advisory Committee Meetings
Workshops
- Clinical Trial Design for Hospital-Acquired Pneumonia and Ventilator-Associated Pneumonia; Public Workshop March 31 - April 1, 2009
- Clinical Trial Design for Community-Acquired Pneumonia; Public Workshop January 17-18, 2008
- Antimicrobial Resistance & Drug Development FDA/IDSA/ISAP Working Group Presentations and Transcripts April 15-16, 2004
Guidance Documents
- Guidances (Drugs)
- Acute Bacterial Exacerbations of Chronic Bronchitis in Patients with Chronic Obstructive Pulmonary Disease: Developing Antimicrobial Drugs for Treatment (PDF - 422KB)
- Acute Bacterial Otitis Media: Developing Drugs for Treatment (PDF - 173KB)
- Acute Bacterial Sinusitis — Developing Antimicrobial Drugs for Treatment (PDF - 155KB)
- Community-Acquired Pneumonia — Developing Antimicrobial Drugs for Treatment (PDF - 418KB)
- Influenza: Developing Drugs for Treatment and/or Prophylaxis (PDF - 225KB)
- Updating Labeling for Susceptibility Test Information in Systemic Antibacterial Drug Products and Antimicrobial Susceptibility Testing Devices (PDF - 143KB)
Additional FDA Information
- Antimicrobial Resistance (CDC)
- Antimicrobial Resistance
Center for Veterinary Medicine - Public Health Focus
An archive of featured topics and public health issues - National Institute of Allergy and Infectious Diseases – Antimicrobial Drug Resistance
- Combating Antibiotic Resistance
FDA Consumer Update - World Health Organization – Antimicrobial Resistance

